Delivery of novel macromolecular drugs against HIV-1

Expert Opinion on Biological Therapy

Volumn 1, Issue 6, 2001, Pages 949-970

  Düzgünes, Nejat ^a   Simões, Sérgio ^b,c   Konopka, Krystyna ^a   Rossi, John J ^e   Pedroso De Lima, Maria C ^c,d  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b Laboratory of Pharmaceutical Technology   (Portugal)

^c Center for Neuroscience   (Portugal)

^d UNIVERSITY OF COIMBRA   (Portugal)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

adeno associated virus; antisense oligonucleotide; cationic liposome; gene silencing; gene therapy; HIV; lentiviral vector; MoMuLV; pH sensitive liposome; Pol III; retroviral vector; ribozyme; viral vector

Indexed keywords

ANTI HIV AGENTS; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTISENSE OLIGONUCLEOTIDE; RIBOZYME;

DNA VECTOR; DNA VIRUS; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; REVIEW; RNA VIRUS;

ANTI-HIV AGENTS; DNA VIRUSES; GENETIC VECTORS; HIV-1; OLIGONUCLEOTIDES, ANTISENSE; RNA VIRUSES; RNA, CATALYTIC;

EID: 0035514271     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.1.6.949     Document Type: Article

References (234)

1. DE CLERCQ E: Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections. J. Med. Chem. (1995) 38:2491-2517.
2. POWDERLY WG: Current approaches to treatment for HIV-1 infection. J Neurovirol (2000) 6(Suppl. 1):S8-S13.
3. BONFANTI P, CAPETTI A, RIZZARDINI G: HIV disease treatment in the era of HAART. Biomed. Pharmacother. (1999) 53:93-105.
4. MONTANER JSG, MONTESSORI V, HARRIGAN R, O'SHAUGHNESSY M, HOGG R: Antiretroviral therapy: 'the state of the art'. Biomed. Pharmacother. (1999) 53:63-72.
5. TOMASSELLI AG, HEINRIKSON RL: Targeting the HIV-protease in AIDS therapy: a current clinical perspective. Biochim. Biophys. Acta (2000) 1477:189-214.
6. CONWAY B, ROUTY J-P, SÉKALY R-P: Combination therapy for HIV: towards long term control of disease progression. Expert Opin. Invest. Drugs (1998) 7:941-961.
7. HANNA GJ, D'AQUILA RT: Antiretroviral drug resistance in HIV-1. Curr. Infect. Dis. Rep. (1999) 1:289-297.
8. ERICE A, BALFOUR HHJR: Resistance of human immunodeficiency virus type 1 to antiretroviral agents: A review. Clin. Infect. Dis. (1994) 18:149-156.
9. BODEN D, MARKOWITZ M: Resistance to human immunodeficiency virus Type 1 protease inhibitors. Antimicrob. Agents Chemother. (1998) 42:2775-2783.
10. BUSHMAN F, LANDAU NR, EMINI EA: New developments in the biology and treatment of HIV. Proc. Natl. Acad. Sci. USA (1998) 95:11041-11042.
11. CHESNEY MA, ICKOVICS J, HECHT FM, SIKIPA G, RABKIN J: Adherence: a necessity for successful HIV combination therapy. AIDS (1999) 13(Suppl. A):S271-S278.
12. DESCAMPS D, FLANDRE P, CALVEZ V et al.: Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur la SIDA 072) study team. JAMA (2000) 283:205-211.
13. DÜZGÜNES N: Treatment of human immunodeficiency virus, Mycobacterium avium and Mycobacterium tuberculosis infections by liposome-encapsulated drugs. In: Medical Applications of Liposomes. Lasic DD, Papahadjopoulos D (Eds.), Elsevier Science B.V., Amsterdam (1998):189-219.
14. ORR RM, O'NEILL CF: Patent review: Therapeutic applications for antisense oligonucleotides. Curr. Opin. Mol. Ther. (2000) 2:325-331.
15. THIERRY AR, TAKLE GB. Liposomes as a delivery system for antisense and ribozyme compounds. In: Delivery Strategies for Antisense Oligonucleotide Therapeutics. Akhtar S (Ed.), CRC Press, Boca Raton, FL, (1995):199-221.
16. MATSUKURA M, ZON G, SHINOZUKA K et al.: Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc. Natl. Acad. Sci. USA (1989) 86:4244-4248.
17. STEIN CA, NECKERS LM, NAIR BC, MUMBAUER S, HOKE G, PAL R: Phosphorothioate oligodeoxycytidine interferes with binding of HIV-1 gp120 to CD4. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. (1991) 4:686-693.
18. LISZIEWICZ J, SUN D, KLOTMAN M, AGRAWAL S, ZAMECNIK P, GALLO R: Specific inhibition of human immunodeficiency virus Type 1 replication by antisense oligonucleotides: An in vitro model for treatment. Proc. Natl. Acad. Sci. USA (1992) 89:11209-11213.
19. LISZIEWICZ J, SUN D, WEICHOLD FF et al.: Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus Type 1 in human peripheral blood cells. Proc. Natl. Acad. Sci USA (1994) 91:7942-7946.
20. WEICHOLD FF, LISZIEWICZ J, ZEMAN RA et al.: Antisense phosphorothioate oligodeoxynucleotides alter HIV Type 1 replication in cultured human macrophages and peripheral blood mononuclear cells. AIDS Res. Hum. Retroviruses (1995) 11:863-868.
21. WAGNER RW, FLANAGAN WM: Antisense technology and prospects for therapy of viral infections and cancer. Mol. Med. Today (1997) 3:31-38.
22. MATTEUCCI MD, WAGNER RW: In pursuit of antisense. Nature (1996) 384(Suppl.):20-22.
23. DÜZGÜNES N, PRETZER E, SIMÕES S et al.: Liposome-mediated delivery of antiviral agents to human immunodeficiency virus-infected cells. Mol. Membr. Biol (1999) 16:111-118.
24. YAMAGUCHI K, PAPP B, ZHANG DZ, ALI AN, AGRAWAL S, BYRN RA: The multiple inhibitory mechanisms of GEM 91(R), a gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus Type 1. AIDS Res. Hum. Retroviruses (1997) 13:545-554.
25. COOK PD. Antisense medicinal chemistry. In: Antisense Research and Application. Crooke ST (Ed.), Springer-Verlag, Berlin (1998):51-92.
26. AKHTAR S, HUGHES MD, KHAN A et al.: The delivery of antisense therapeutics. A d v. Drug Deliv. Rev. (2000) 44:3-21.
27. GARCIA-CHAUMONT C, SEKSEK O, GRZYBOWSKA J, BOROWSKI E, BOLARD J: Delivery systems for antisense oligonucleotides. Pharmacol. Ther. (2000) 87:255-277.
28. BANGHAM AD: Surrogate cells or Trojan horses. The discovery of liposomes. BioEssays (1995) 17:1081-1088.
29. LASIC D, MARTIN F: Stealth Liposomes. CRC Press, Boca Raton, Florida, USA (Eds) (1995): 1-289.
30. LASIC DD, PAPAHADJOPOULOS D: In: Medical Applications of Liposomes. Elsevier Science B.V., Amsterdam (Eds) (1998): 1-7.
31. BAKKER-WOUDENBERG IAJM, VAN ETTEN EWM: Long-circulating liposomes containing antibacterial and antifungal agents. In: Medical Applications of Liposomes. Lasic DD, Papahadjopoulos D (Eds.), Elsevier Science B.V., Amsterdam (1998):181-188.
32. GOREN D, GABIZON A: Pharmacologic advantages of anthracyclines encapsulated in poly-ethylene-glycol coated Stealth liposomes. In: Medical Applications of Liposomes. Lasic DD, Papahadjopoulos D (Eds.), Elsevier Science B.V., Amsterdam (1998):259-274.
33. THIERRY AR, DRITSCHILO A: Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res. (1992) 20:5691-5698.
34. TARI AM, TUCKER SD, DEISSEROTH A, LOPEZ-BERESTEIN G: Liposomal delivery of methylphosphonate antisense oligodeoxynucleotides in chronic myelogenous leukemia. Blood (1994) 84:601-607.
35. TARI A, KHODADADIAN M, ELLERSON D, DEISSEROTH A, LOPEZ-BERESTEIN G: Liposomal delivery of oligodeoxynucleotides. Leuk. Lymphoma (1996) 21:93-97.
36. LEONETTI J-P, MACHY P, DEGOLS G, LEBLEU B, LESERMAN L: Antibody-targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibit viral replication. Proc. Natl. Acad. Sci. USA (1990) 87:2448-2451.
37. STEVENSON M, IVERSEN PL: Inhibition of human immunodeficiency virus Type 1-mediated cytopathic effects by poly(L-lysine)-conjugated synthetic antisense oligonucleotides. J. Gen. Virol. (1989) 70:2673-2682.
38. BENNETT FC, CHIANG MY, CHAN HC, SHOEMAKER JEE, MIRABELLI CK: Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. (1992) 41:1023-1033.
39. LAPPALAINEN K, URTTI A, SÖDERLING E, JÄÄSKELÄINEN I, SYRJÄNEN K, SYRJÄNEN S: Cationic liposomes improve stability and intracellular delivery of antisense oligonucleotides into CaSki cells. Biochim. Biophys. Acta (1994) 1196:201-208.
40. LAPPALAINEN K, PIRILÄ L, JÄÄSKELÄINEN I, SYRJÄNEN K, SYRJÄNEN S: Effects of liposomal antisense oligonucleotides on mRNA and protein levels of the HPV 16 E7 oncogene. Anti-Cancer Res. (1998) 16:2485-2492.
41. KABANOV AV, VINOGRADOV SV, SUZDALTSEVA YG, ALAKHOV VY: Water-soluble block polycations as carriers for oligonucleotide delivery. Bioconjug. Chem. (1995) 6:639-643.
42. HUGHES JA, ARONSOHN AI, AVRUTSKAYA AV, JULIANO RL: Evaluation of adjuvants that enhance the effectiveness of antisense oligodeoxynucleotides. Pharm. Res. (1996) 13:404-410.
43. ZELPHATI O, SZOKA FC Jr.: Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharm. Res. (1996) 13:1367-1372.
44. ZELPHATI O, SZOKA FC Jr.: Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl. Acad. Sci. USA (1996) 93:11493-11498.
45. ROPERT C, LAVIGNON M, DUBERNET C, COUVREUR P, MALVY C: Oligonucleotides encapsulated in pH sensitive liposomes are efficient toward Friend retrovirus. Biochem. Biophys. Res. Commun. (1992) 183:879-885.
46. DÜZGÜNES N, FLASHER D, PRETZER E et al: Liposome-mediated therapy of human immunodeficiency virus type-1 and mycobacterium infections. J. Liposome Res. (1995) 5:669-691.
47. DE OLIVEIRA MC, FATTAL E, COUVREUR P et al.: pH-Sensitive liposomes as a carrier for oligonucleotides: a physico-chemical study of the interaction between DOPE and a 15-mer oligonucleotide in quasi-anhydrous samples. Biochim. Biophys. Acta Bio-Memb. (1998) 1372:301-310.
48. DE OLIVEIRA MC, ROSILIO V, LESIEUR P et al.: pH-sensitive liposomes as a carrier for oligonucleotides: a physico-chemical study of the interaction between DOPE and a 15-mer oligonucleotide in excess water. Biophys. Chem. (2000) 87:127-137.
49. RENNEISEN K, LESERMAN L, MATTHES E, SCHRÖDER HC, MÜLLER WEG: Inhibition of expression of human immunodeficiency virus-1 in vitro by antibody-targe ted liposomes containing antisense RNA to the env region. J. Biol. Chem. (1990) 265:16337-16342.
50. ZELPHATI O, ZON G, LESERMAN L: Inhibition of HIV-1 replication in cultured cells with antisense oligonucleotides encapsulated in immunoliposomes. Antisense Res. Dev. (1993) 3:323-338.
51. ZELPHATI O, WAGNER E, LESERMAN L: Synthesis and anti-HIV activity of thiocholesteryl-coupled phosphodiester antisense oligonucleotides incorporated into immunoliposomes. Antiviral Res. (1994) 25:13-25.
52. ZELPHATI O, IMBACH J-L, SIGNORET N, ZON G, RAYNER B, LESERMAN L: Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms. Nucleic Acids Res. (1994) 22:4307-4314.
53. SIMÕES S, PIRES P, DÜZGÜNES N, PEDROSO DE LIMA MC: Cationic liposomes as gene transfer vectors: Barriers to successful application in gene therapy. Curr. Opin. Mol Ther. (1999) 1:147-157.
54. FELGNER PL, GADEK TR, HOLM M et al.: Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl. Acad. Sci. USA (1987) 84:7413-7417.
55. ROJANASAKUL Y: Antisense oligonucleotide therapeutics: drug delivery and targeting. Adv. Drug Deliv. Rev. (1996) 18:115-131.
56. ANAZODO MI, WAINBERG MA, FRIESEN AD, WRIGHT JA: Sequence-specific inhibition of gene expression by a novel antisense oligodeoxynucleotide phosphorothioate directed against a nonregulatory region of the human immunodeficiency virus Type 1 genome. J. Virol (1995) 69:1794-1801.
57. LAVIGNE C, THIERRY AR: Enhanced antisense inhibition of human immunodeficiency virus Type 1 in cell cultures by DLS delivery system. Biochem. Biophys. Res. Commun. (1997) 237:566-571.
58. PLANK C, MECHTLER K, SZOKA FCJR, WAGNER E: Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum. Gene Ther. (1996) 7:1437-1446.
59. ZELPHATI O, UYECHI LS, BARRON LG, SZOKA FCJR: Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells. Biochim. Biophys. Acta (1998) 1390:119-133.
60. LITZINGER DC, BROWN JM, WALA I et al: Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim. Biophys. Acta (1996) 1281:139-149.
61. MEYER O, KIRPOTIN D, HONG K et al: Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides. J. Biol. Chem. (1998) 273:15621-15627.
62. CONNOR J, HUANG L: Efficient cytoplasmic delivery of a fluorescent dye by pH-sensitive liposomes. J. Cell Biol. (1985) 101:582-589.
63. STRAUBINGER RM, DÜZGÜNES N, PAPAHADJOPOULOS D: pH-sensitive liposomes mediate cytoplasmic delivery of encapsulated macromolecules. FEBS Lett. (1985) 179:148-154.
64. DÜZGÜNES N, STRAUBINGER RM, BALDWIN PA, PAPAHADJOPOULOS D: pH-Sensitive liposomes: Introduction of foreign substances into cells. In: Membrane Fusion. WILSCHUT J, HOEKSTRA D (Eds.) Marcel Dekker, Inc., New York (1991):713-730.
65. TORCHILIN VP, ZHOU F, HUANG L: pH-Sensitive liposomes. J. Liposome Res. (1993) 3:201-255.
66. CHU C-J, DIJKSTRA J, LAI M-Z, HONG K, SZOKA FC: Efficiency of cytoplasmic delivery by pH-sensitive liposomes to cells in culture. Pharm. Res. (1990) 7:824-834.
67. STRAUBINGER RM: pH-sensitive liposomes for delivery of macromolecules into cytoplasm of cultured cells. Methods Enzymol. (1993) 221:361-376.
68. DÜZGÜNES N, SIMÕES S, SLEPUSHKIN V et al.: Enhanced inhibition of HIV-1 replication in macrophages by antisense oligonucleotides, ribozymes and acyclic nucleoside phosphonate analogs delivered in pH-sensitive liposomes. Nucleosides Nucleotides Nucleic Acids (2001) 20:515-523.
69. SELVAM MP, BUCK SM, BLAY RA, MAYNER RE, MIED PA, EPSTEIN JS: Inhibition of HIV replication by immunoliposomal antisense oligonucleotide. Antiviral Res. (1996) 33:11-20.
70. SLEPUSHKIN VA, SIMÕES S, DAZIN P et al: Sterically stabilized pH-sensitive liposomes: Intracellular delivery of aqueous contents and prolonged circulation in vivo. J. Biol. Chem. (1997) 272:2382-2388.
71. ALLEN TM, HANSEN CB, GUO LSS: Subcutaneous administration of liposomes: A comparison with the intravenous and intraperitoneal routes of injection. Biochim. Biophys. Acta (1993) 1150:9-16.
72. PANTALEO G, GRAZIOSI C, DEMAREST JF et al: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature (1993) 362:355-358.
73. PANTALEO G, FAUCI AS: New concepts in the immunopatho genesis of HIV infection. Ann. Rev. Immunol. (1995) 13:487-512.
74. SCHEULE RK: The role of CpG motifs in immunostimulation and gene therapy. Adv. Drug Deliv. Rev. (2000) 44:119-134.
75. HORNER AA, DATTA SK, TAKABAYASHI K et al.: Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. J. Immunol. (2001) 167:1584-1591.
76. MOSS RB, DIVELEY J, JENSEN FC, GOUVEIA E, SAVARY J, CARLO DJ: HIV-specific CD4(+) and CD8(+) immune responses are generated with a gp 120-depleted, whole-killed HIV-1 immunogen with CpG immunostimulatory sequences of DNA. J. Interferon. Cytokine Res. (2000) 20:1131-1137.
77. SARVER N, CANTIN EM, CHANG PS et al: Ribozymes as potential anti-HIV-1 therapeutic agents. Science (1990) 247:1222-1225.
78. ROSSI JJ, SARVER N: Catalytic antisense RNA (ribozymes): Their potential and use as anti-HIV-1 therapeutic agents. Adv. Exp. Med. Biol. (1992) 312:95-109.
79. ZAIA JA, CHATTERJEE S, WONG KK, ELKINS D, TAYLOR NR, ROSSI JJ: Status of ribozyme and antisense-based developmental approaches for anti-HIV-1 therapy. Ann. NY Acad. Sci. (1992) 660:95-106.
80. ROSSI JJ, ELKINS D, ZAIA JA, SULLIVAN S: Ribozymes as anti-HIV-1 therapeutic agents: principles, applications, and problems. AIDS Res. Hum. Retroviruses (1992) 8:183-189.
81. MUOTRI AR, PEREIRA LD, VASQUES LD, MENCK CFM: Ribozymes and the anti-gene therapy: how a catalytic RNA can be used to inhibit gene function. Gene (1999) 237:303-310.
82. YU M, POESCHLA E, WONG-STAAL F: Progress towards gene therapy for HIV infection. Gene Ther (1994) 1:13-26.
83. ROSSI JJ: Ribozyme therapy for HIV infection. Adv. Drug Deliv. Rev. (2000) 44:71-78.
84. CHANG PS, CANTIN EM, ZAIA JA et al: Ribozyme-mediated site-specific cleavage of HIV-1 gene. Clin. Biotech. (1990) 2:23-31.
85. VAISHNAV YN, WONG-STAAL F: The biochemistry of AIDS. Ann. Rev. Biochem. (1991) 60:577-630.
86. KIJIMA H, ISHIDA H, OHKAWA T, KASHANI-SABET M, SCANLON KJ: Therapeutic applications of ribozymes. Pharmacol. Ther. (1995) 68:247-267
87. DRAGIC T, LITWIN V, ALLAWAY GP et al: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 381:667-673.
88. FENG Y, BRODER CC, KENNEDY PE, BERGER EA: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G-protein-coupled receptor. Science (1996) 272:872-877.
89. GOILA R, BANERJEA AC: Sequence specific cleavage of the HIV-1 co-receptor CCR5 gene by a hammer-head ribozyme and a DNA-enzyme: Inhibition of the co-receptor function by DNA-enzyme. FEBS Lett. (1998) 436:233-238.
90. GONZALEZ MA, SERRANO F, LLORENTE M, ABAD JL, GARCIA-ORTIZ MJ, BERNAD A: A hammerhead ribozyme targeted to the human chemokine receptor CCR5. Biochem. Biophys. Res. Commun. (1998) 251:592-596.
91. FENG Y, LEAVITT M, TRITZ R et al.: Inhibition of CCR5-dependent HIV-1 infection by hairpin ribozyme gene therapy against CC-chemokine receptor 5. Virology (2000) 276:271-278.
92. HEIDENREICH O, PIEKEN W, ECKSTEIN F: Chemically modified RNA: approaches and applications. FASEB J. (1993) 7:90-96.
93. CHRISTOFFERSEN RE, MARR JJ: Ribozymes as human therapeutic agents. J. Med. Chem. (1995) 38:2023-2037.
94. TAYLOR NR, KAPLAN BE, SWIDERSKI P, LI H, ROSSI JJ: Chimeric DNA-RNA hammerhead ribozyme have enhanced in vitro catalytic efficiency and increased stability in vivo. Nucleic Acids Res. (1992) 17:4559-4565.
95. MALONE RW, FELGNER PL, VERMA IM: Cationic liposome-mediated RNA transfection. Proc. Natl. Acad. Sci. USA (1989) 86:6077-6081.
96. ROSSI JJ, CANTIN EM, SARVER N, CHANG PF: The potential use of catalytic RNAs in therapy of HIV infection and other diseases. Pharmacol Ther. (1991) 50:245-254.
97. KONOPKA K, ROSSI JJ, SWIDERSKI P, SLEPUSHKIN VA, DÜZGÜNES N: Delivery of an anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes. Biochim. Biophys. Acta (1998) 1372:55-68.
98. BRAMLAGE B, LUZI E, ECKSTEIN F: HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture. Nucleic Acids Res. (2000) 28:4059-4067.
99. KARIKÓ K, MEGYERI K, XIAO Q, BARNATHAN ES: Lipofectin-aided cell delivery of ribozyme targeted to human urokinase receptor mRNA. FEBS Lett. (1994) 352:41-44.
100. SNYDER DS, WU Y, WANG JL et al: Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood (1993) 82:600-605.
101. LEOPOLD LH, SHORE SK, NEWKIRK TA, REDDY RMV, REDDY EP: Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias. Blood (1995) 85:2162-2170.
102. KIEHNTOPF M, BRACH MA, LICHT T et al: Ribozyme-mediated cleavage of the MDR-1 transcript restores chemosensitivity in previously resistant cancer cells. EMBO J. (1994) 13:4645-4652.
103. GU J-L, VEERAPANANE D, ROSSI J, NATARAJAN R, THOMAS L, NADLER J: Ribozyme-mediated inhibition of expression of leukocyte-type 12-lipoxygenase in porcine aortic vascular smooth muscle cells. Circ. Res. (1995) 77:14-20.
104. WELCH PJ, BARBER JR, WONG-STAAL F: Expression of ribozymes in gene transfer systems to modulate target RNA levels. Curr. Opin. Biotechnol (1998) 9:486-496.
105. ARNDT GM, RANK GH: Co-localization of antisense RNAs and ribozymes with their target mRNAs. Genome (1997) 40:785-797.
106. BERTRAND E, CASTANOTTO D, ZHOU C et al: The expression cassette determines the functional activity of ribozyme in mammalian cells by controlling their intracellular localization. RNA (1997) 3:75-88.
107. HORMES R, HOMANN M, OELZE I et al: The subcellular localization and length of hammerhead ribozymes determine efficacy in human cells. Nucleic Acids Res. (1997) 24:769-775.
108. CAMERON FH, JENNINGS PA: Multiple domains in a ribozyme construct confer increased suppressive activity in monkey cells. Antisense Res. Dev (1994) 4:87-95.
109. KONOPKA K, LEE NS, ROSSI J, DÜZGÜNES N: Rev-binding aptamer and CMV promoter act as decoys to inhibit HIV replication. Gene (2000) 255:235-244.
110. THOMPSON JD, AYERS DF, MALMSTROM TA et al.: Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter. Nucleic Acids Res. (1995) 23:2259-2268.
111. GOOD PD, KROKOS AJ, LI SXL et al: Expression of small, therapeutic RNAs in human cell nuclei. Gene Ther. (1997) 4:45-54.
112. SUN LQ, WARRILOW D, WANG L, WITHERINGTON C, MACPHERSON J, SYMONDS G: Ribozyme-mediated suppression of Moloney murine leukemia virus and human immunodeficiency virus Type I replication in permissive cell lines. Proc. Natl. Acad. Sci. USA (1994) 91:9715-9719.
113. SUN LQ, WANG L, GERLACH WL, SYMONDS G: Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA. Nucleic Acids Res. (1995) 23:2909-2913.
114. MICHIENZI A, CONTI L, VARANO B, PRISLEI S, GESSANI S, BOZZONI I: Inhibition of human immunodeficiency virus Type 1 replication by nuclear chimeric anti-HIV ribozymes in a human T lymphoblastoid cell line. Hum. Gene Ther. (1998) 9:621-628.
115. YAMADA O, KRAUS G, LUZNIK L, YU M, WONG-STAAL F: A chimeric human immunodeficiency virus Type 1 (HIV-1) minimal Rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1. J. Virol. (1996) 70:1596-1601.
116. OJWANG JO, HAMPEL A, LOONEY DJ, WONG-STAAL F, RAPPAPORT J: Inhibition of human immunodeficiency virus Type 1 expression by a hairpin ribozyme. Proc. Natl. Acad. Sci. USA (1992) 89:10802-10806.
117. YU M, OJWANG J, YAMADA O et al.: A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus Type 1. Proc. Natl. Acad. Sci. USA (1993) 90:6340-6344.
118. CHEN C-J, BANERJEA AC, HARMISON GG, HAGLUND K, SCHUBERT M: Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication-Potential effectiveness against most presently sequenced HIV-1 isolates. Nucleic Acids Res. (1992) 20:4581-4589.
119. KONOPKA K, DÜZGÜNES N, ROSSI J, LEE NS: Receptor ligand-facilitated cationic liposome delivery of anti-HIV-1 Rev binding aptamer and ribozyme DNAs. J. Drug Targeting (1998) 5:247-259.
120. CHENG PW: Receptor ligand-facilitated gene transfer: Enhancement of liposome-mediated gene transfer and expression by transferrin. Hum. Gene Ther. (1996) 7:275-282.
121. SIMÕES S, SLEPUSHKIN V, GASPAR R, PEDROSO DE LIMA MC, DÜZGÜNES N: Gene delivery by negatively charged ternary complexes of DNA, cationic liposomes and transferrin or fusigenic peptides. Gene Ther. (1998) 5:955-964.
122. TRAPNELL BC, GORZIGLIA M: Gene therapy using adenoviral vectors. Curr. Opin. Biotechnol. (1994) 5:617-625.
123. SINGHAL A, HUANG L. Gene transfer in mammalian cells using liposomes as carriers. In: Gene Therapeutics: Methods and Applications of Direct Gene Transfer. Wolf JA (Ed.), Birkhäuser, Boston (1994): 118-142.
124. CLARK PR, HERSH EM: Cationic lipid-mediated gene transfer: Current concepts. Curr. Opin. Mol. Therapeut. (1999) 1:158-176.
125. TEMPLETON NS, LASIC DD: New directions in liposome gene delivery. Mol. Biotechnol. (1999) 11:175-180.
126. DÜZGÜNES N, SIMÕES S, PIRES P, PEDROSO DE LIMA MC: Gene delivery by cationic lipid-DNA complexes. In: Polymeric Biomaterials. Dumitriu S (Ed.), Marcel Dekker, New York (2001) (In Press).
127. LASIC DD, TEMPLETON NS: Liposomes in gene therapy. Adv. Drug Deliv. Rev. (1996) 20:221-266.
128. BALLY MB, HARVIE P, WONG FMP, KONG S, WASAN EK, REIMER DL: Biological barriers to cellular delivery of lipid-based DNA carriers. Adv. Drug Deliv. Rev. (1999) 38:291-315.
129. TROS DE ILARDUYA C, DÜZGÜNES N: Efficient gene transfer by transferrin lipoplexes in the presence of serum. Biochim. Biophys. Acta (2000) 1463:333-342.
130. SIMÕES S, SLEPUSHKIN V, PIRES P, GASPAR R, PEDROSO DE LIMA MC, DÜZGÜNES N: Human serum albumin enhances DNA transfection by lipoplexes and confers resistance to inhibition by serum. Biochim. Biophys. Acta (2000) 1463:459-469.
131. SCHEULE RK, ST.GEORGE JA, BAGLEY RG et al: Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung. Hum. Gene Ther. (1997) 8:689-707.
132. LIU F, QI H, HUANG L, LIU D: Factors controlling the efficiency of cationic lipid-mediated transfection in vivo via intravenous administration. Gene Ther. (1997) 4:517-523.
133. ZHU N, LIGGITT D, LIU Y, DEBS R: Systemic gene expression after intravenous DNA delivery into adult mice. Science (1993) 261:209-211.
134. SAEKI Y, WATAYA-KANEDA M, TANAKA K, KANEDA Y: Sustained transgene expression in vitro and in vivo using an Epstein-Barr virus replicon vector system combined with HVJ liposomes. Gene Ther. (1998) 5:1031-1037.
135. TU G, KIRCHMAIER AL, LIGGITT D et al: Non-replicating Epstein-Barr virus-based plasmids extend gene expression and can improve gene therapy in vivo. J. Biol. Chem. (2000) 275:30408-30414.
136. OTOMO T, YAMAMOTO S, MORISHITA R, KANEDA Y: EBV replicon vector system enhances transgene expression in vivo: applications to cancer gene therapy. J. Gene Med. (2001) 3:345-352.
137. ANDERSON WF: Human gene therapy. Science (1992) 256:808-813.
138. MILLER AD: Human gene therapy comes of age. Nature (1992) 357:455-460.
139. NALDINI L, BLOMER U, GALLAY P et al: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (1996) 272:263-267.
140. NALDINI L, VERMA IM: Lentiviral vectors. Adv. Virus Res. (2000) 55:599-609.
141. CURRAN MA, KAISER SM, ACHACOSO PL, NOLAN GP: Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. Mol. Ther. (2000) 1:31-38.
142. POESCHLA EM, WONG-STAAL F, LOONEY DJ: Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nature Med. (1998) 4:354-357.
143. WHITE SM, RENDA M, NAM NY et al: Lentivirus vectors using human and simian immunodeficiency virus elements. J. Virol. (1999) 73:2832-2840.
144. BERKNER KL: Expression of heterologous sequences in adenoviral vectors. Curr. Top. Microbiol. Immunol. (1992) 158:39-66.
145. SMITH TA, MEHAFFEY MG, KAYDA DB et al: Adenovirus mediated expression of therapeutic plasma levels of human Factor IX in mice. Nature Genet. (1993) 5:397-402.
146. LI Q, KAY MA, FINEGOLD M, STRATFORD-PERRICAUDET LD, WOO SL: Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum. Gene Ther. (1993) 4:403-409.
147. BRIAND P, KAHN A: Values and limits of adenoviral vectors for gene transfer in vivo. Pathol. Biol. (Paris) (1993) 41:663-671.
148. MCLAUGHLIN SK, COLLIS P, HERMONAT PL, MUZYCZKA N: Adeno-associated virus general transduction vectors: analysis of proviral structures. J. Virol. (1988) 62:1963-1973.
149. HERMONAT PL, MUZYCZKA N: Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc. Natl. Acad. Sci. USA (1984) 81:6466-6470.
150. ROLLING F, SAMULSKI RJ: AAV as a viral vector for human gene therapy. Generation of recombinant virus. Mol. Biotechnol. (1995) 3:9-15.
151. CHIRICO J, TREMPE JP: Optimization of packaging of adeno-associated virus gene therapy vectors using plasmid transfections. J. Virol. Methods (1998) 76:31-41.
152. PODSAKOFF G, WONG KK, CHATTERJEE S: Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. J. Virol. (1994) 68:5656-5666.
153. CHATTERJEE S, LI W, WONG CA et al: Transduction of primitive human marrow and cord blood-derived hematopoietic progenitor cells with adeno-associated virus vectors. Blood (1999) 93:1882-1894.
154. KRISKY DM, MARCONI PC, OLIGINO TJ et al: Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications. Gene Ther. (1998) 5:1517-1530.
155. MARCONI P, SIMONATO M, ZUCCHINI S et al.: Replication-defective herpes simplex virus vectors for neurotrophic factor gene transfer in vitro and in vivo. Gene Ther. (1999) 6:904-912.
156. GOINS WF, KRISKY D, MARCONI P et al.: Herpes simplex virus vectors for gene transfer to the nervous system. J. Neurovirol. (1997) 3(Suppl. 1):S80-S88.
157. STRAYER DS: Gene therapy using SV40-derived vectors: what does the future hold? J. Cell Physiol. (1999) 181:375-384.
158. WALTHER W, STEIN U: Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs (2000) 60:249-271.
159. TAL J: Adeno-associated virus-based vectors in gene therapy. J. Biomed. Sci. (2000) 7:279-291.
160. ALEMANY R, BALAGUE C, CURIEL DT: Replicative adenoviruses for cancer therapy. Nat. Biotechnol. (2000) 18:723-727.
161. PALU G, PAROLIN C, TAKEUCHI Y, PIZZATO M: Progress with retroviral gene vectors. Rev. Med. Virol. (2000) 10:185-202.
162. FINK DJ, DELUCA NA, YAMADA M, WOLFE D P, GLORIOSO JC: Design and application of HSV vectors for neuroprotection. Gene Ther. (2000) 7:115-119.
163. STONE D, DAVID A, BOLOGNANI F, LOWENSTEIN PR, CASTRO MG: Viral vectors for gene delivery and gene therapy within the endocrine system. J. Endocrinol. (2000) 164:103.
164. MIHALY J, HOGGA I, BARGES S et al.: Chromatin domain boundaries in the Bithorax complex. Cell. Mol. Life Sci. (1998) 54:60-70.
165. GLAZKOV MV: Boundaries of structure-functional units (domains) of eukaryotic chromosomes. Genetika (1998) 34:593-604.
166. WOLFE AP: Gene regulation. Insulating chromatin. Curr. Biol. (1994) 4:85-87.
167. ZHONG XP, KRANGEL MS: An enhancer-blocking element between alpha and delta gene segments within the human T cell receptor alpha/delta locus. Proc. Natl. Acad. Sci. USA (1997) 94:5219-5224.
168. CHUNG JH, WHITELEY M, FELSENFELD G: A 5′ element of the chicken beta-globin domain serves as an insulator in human erythroid cells and protects against position effect in Drosophila. Cell (1993) 74:505-514.
169. RIVELLA S, CALLEGARI JA, MAY C, TAN CW, SADELAIN M: The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. J. Virol. (2000) 74:4679-4687.
170. STEINWAERDER DS, LIEBER A: Insulation from viral transcriptional regulatory elements improves inducible transgene expression from adenovirus vectors in vitro and in vivo. Gene Ther. (2000) 7:556-567.
171. EMERY DW, STAMATOYANNOPOULOS G: Stem cell gene therapy for the beta-chain hemoglobinopathies. Problems and progress. Ann. NY Acad. Sci. (1999) 872:94-107.
172. RIVELLA S, SADELAIN M: Genetic treatment of severe hemoglobinopathies: the combat against transgene variegation and transgene silencing. Semin. Hematol (1998) 35:112-125.
173. NEFF T, SHOTKOSKI F, STAMATOYANNOPOULOS G: Stem cell gene therapy, position effects and chromatin insulators. Stem Cells (1997) 15:265-271.
174. CHUNG JH, BELL AC, FELSENFELD G: Characterization of the chicken beta-globin insulator. Proc. Natl. Acad. Sci. USA (1997) 94:575-580.
175. KALOS M, FOURNIER RE: Position-independent transgene expression mediated by boundary elements from the apolipoprotein B chromatin domain. Mol Cell Biol. (1995) 15:198-207.
176. KLEHR D, SCHLAKE T, MAASS K, BODE J: Scaffold-attached regions (SAR elements) mediate transcriptional effects due to butyrate. Biochem. (1992) 31:3222-3229.
177. POLJAK L, SEUM C, MATTIONI T, LAEMMLI UK: SARs stimulate but do not confer position independent gene expression. Nucleic Acids Res. (1994) 22:4386-4394.
178. AGARWAL M, AUSTIN TW, MOREL F, CHEN J, BOHNLEIN E, PLAVEC I: Scaffold attachment region-mediated enhancement of retroviral vector expression in primary T cells. J. Virol (1998) 72:3720-3728.
179. SHIMIZU Y, OKA Y, OGAWA H, KISHIMOTO T, SUGIYAMA H: Regulation of Thy-1 gene expression by the methylation of the 5' region of Thy-1 gene and intracellular regulatory factors in immature B cells. Immunol. Invest. (1992) 21:183-191.
180. SZYF M, TANIGAWA G, McCARTHY PLJR: A DNA signal from the Thy-1 gene defines de novo methylation patterns in embryonic stem cells. Mol Cell Biol. (1990) 10:4396-4400.
181. RYU WS, MERTZ JE: Simian virus 40 late transcripts lacking excisable intervening sequences are defective in both stability in the nucleus and transport to the cytoplasm. J. Virol. (1989) 63:4386-4394.
182. HUANG MT, GORMAN CM: Intervening sequences increase efficiency of RNA 3' processing and accumulation of cytoplasmic RNA. Nucleic Acids Res. (1990) 18:937-947.
183. MATSUMOTO K, WASSARMAN KM, WOLFFE AP: Nuclear history of a pre-mRNA determines the translational activity of cytoplasmic mRNA. EMBO J. (1998) 17:2107-2121.
184. SHI ST, HUANG P, LI HP, LAI MM: Heterogeneous nuclear ribonucleoprotein A1 regulates RNA synthesis of a cytoplasmic virus. EMBO J. (2000) 19:4701-4711.
185. BRODSKY AS, SILVER PA: Pre-mRNA processing factors are required for nuclear export. RNA (2000) 6:1737-1749.
186. MAUTINO MR, KEISER N, MORGAN RA: Improved titers of HIV-based lentiviral vectors using the SRV-1 constitutive transport element. Gene Ther. (2000) 7:1421-1424.
187. SCHAMBACH A, WODRICH H, HILDINGER M, BOHNE J, KRAUSSLICH HG, BAUM C: Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors. Mol Ther. (2000) 2:435-445.
188. LI B, WYMAN TE, MOUDGIL T, MARRACCI GH, JU CF, MACHIDAC A: Nucleocytoplasmic export of type D simian retrovirus genomic RNA: identification of important genetic subregions and interacting cellular proteins. Virology (1999) 264:37-54.
189. PASQUINELLI AE, ERNST RK, LUND E et al: The constitutive transport element (CTE) of Mason-Pfizer monkey virus (MPMV) accesses a cellular mRNA export pathway. EMBO J. (1997) 16:7500-7510.
190. RIZVI TA, SCHMIDT RD, LEW KA: Mason-Pfizer monkey virus (MPMV) constitutive transport element (CTE) functions in a position-dependent manner. Virology (1997) 236:118-129.
191. BAKER RE, CAMIER S, SENTENAC A, HALL BD: Gene size differentially affects the binding of yeast transcription factor tau to two intragenic regions. Proc. Natl. Acad. Sci. USA (1987) 84:8768-8772.
192. SCHULTZ P, MARZOUKI N, MARCK C, RUET A, OUDET P, SENTENAC A: The two DNA-binding domains of yeast transcription factor tau as observed by scanning transmission electron microscopy. EMBO J. (1989) 8:3815-3824.
193. PAULE MR, WHITE RJ: Survey and summary: transcription by RNA polymerases I and III. Nucleic Acids Res. (2000) 28:1283-1298.
194. SULLENGER BA, CECH TR: Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science (1993) 262:1566-1569.
195. MICHIENZI A, CAGNON L, BAHNER I, ROSSI JJ: Ribozyme-mediated inhibition of HIV 1 suggests nucleolar trafficking of HIV-1 RNA. Proc. Natl. Acad. Sci. USA (2000) 97:8955-8960.
196. MICHIENZI A, PRISLEI S, BOZZONI I: U1 small nuclear RNA chimeric ribozymes with substrate specificity for the Rev pre-mRNA of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA (1996) 93:7219-7224.
197. BARCELLINI-COUGET S, FENARD D, BERTRAND E, SINGER RH, LEFEBVRE JC, DOGLIO A: 3′-End modification of the adenoviral VA1 gene affects its expression in human cells: consequences for the design of chimeric VA1 RNA ribozymes . Antisense Nucleic Acid Drug Dev. (1998) 8:379-390.
198. CAGNON L, CUCCHIARINI M, LEFEBVRE JC, DOGLIO A: Protection of a T-cell line from human immunodeficiency virus replication by the stable expression of a short antisense RNA sequence carried by a shuttle RNA molecule. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. (1995) 9:349-358.
199. DROPULIC B, JEANG K-T: Gene therapy for human immunodeficiency virus infection: Genetic antiviral strategies and targets for intervention. Hum. Gene Ther. (1994) 5:927-939.
200. MORGAN RA: Genetic strategies to inhibit HIV. Mol. Med. Today (1999) 5:454-458.
201. HARRISON GS, LONG CJ, CURIEL TJ, MAXWELL F, MAXWELL IH: Inhibition of human immunodeficiency virus-1 production resulting from transduction with a retrovirus containing an HIV-regulated diphtheria toxin A chain gene. Hum. Gene Ther. (1992) 3:461-469.
202. DINGES MM, COOK DR, KING J, CURIEL TJ, ZHANG XQ, HARRISON GS: HIV-regulated diphtheria toxin A chain gene confers long-term protection against HIV Type 1 infection in the human promonocytic cell line U937. Hum. Gene Ther. (1995) 6:1437-1445.
203. LO KMS, BIASOLO MA, DEHNI G, PALÚ G, HASELTINE WA: Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA. Virology (1992) 190:176-183.
204. YAMADA O, YU M, YEE J-K, KRAUS G, LOONEY D, WONG-STAAL F: Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus Type 1. Gene Ther. (1994) 1:38-45.
205. LEAVITT MC, YU M, YAMADA O et al.: Transfer of an anti-HIV-1 ribozyme gene into primary human lymphocytes. Hum. Gene Ther. (1994) 5:1115-1120.
206. YU M, POESCHLA E, YAMADA O et al: In vitro and in vivo characterization of a second functional hairpin ribozyme against HIV-1. Virology (1995) 206:381-386.
207. SUN LQ, PYATI J, SMYTHE J et al.: Resistance to human immunodeficiency virus Type 1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric trans-activation response element constructs. Proc. Natl. Acad. Sci. USA (1995) 92:7272-7276.
208. ROSENZWEIG M, MARKS DF, HEMPEL D, LISZIEWICZ J, JOHNSON RP: Transduction of CD34+ hematopoietic progenitor cells with an antitat gene protects T-cell and macrophage progeny from AIDS virus infection. J. Virol. (1997) 71:2740-2746.
209. GERVAIX A, SCHWARZ L, LAW P et al: Gene therapy targeting peripheral blood CD34+ hematopoietic stem cells of HIV-infected individuals. Hum. Gene Ther. (1997) 8:2229-2238.
210. BAUER G, VALDEZ P, KEARNS K et al.: Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. Blood (1997) 89:2259-2267.
211. VANDENDRIESSCHE T, CHUAH MKL, CHIANG L, CHANG H-K, ENSOLI B, MORGAN RA: Inhibition of clinical human immunodeficiency virus (HIV) Type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes. J. Virol. (1995) 69:4045-4052.
212. SMITH C, LEE S-W, WONG E et al.: Transient protection of human T-cells from human immunodeficiency virus Type 1 infection by transduction with adeno-associated viral vectors which express RNA decoys. Antiviral Res. (1996) 32:99-115.
213. INOUYE RT, DU B, BOLDT-HOULE D et al.: Potent inhibition of human immunodeficiency virus Type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vector. J. Virol. (1997) 71:4071-4078.
214. MAUTINO MR, MORGAN RA: Potent inhibition of human immunodeficiency virus Type 1 replication by conditionally replicating human immunodeficiency virus-based lentiviral vectors expressing envelope antisense mRNA. Hum. Gene Ther (2000) 11:2025-2037.
215. MAUTINO MR, KEISER N, MORGAN RA: Inhibition of human immunodeficiency virus Type 1 (HIV-1) replication by HIV-1-based lentiviral vectors expressing transdominant Rev. J. Virol. (2001) 75:3590-3599.
216. WONG-STAAL F, POESCHLA EM, LOONEY DJ: A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Hum. Gene Ther. (1998) 9:2407-2425.
217. COOPER D, PENNY R, SYMONDS G et al: A marker study of therapeutically transduced CD4+ peripheral blood lymphocytes in HIV discordant identical twins. Hum. Gene Ther. (1999) 10:1401-1421.
218. KOHN DB, BAUER G, RICE CR et al: A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34 cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood (1999) 94:368-371.
219. AMADO RG, MITSUYASU RT, SYMONDS G et al.: A Phase I trial of autologous CD34+ hematopoietic progenitor cells transduced with an anti-HIV ribozyme. Hum. Gene Ther. (1999) 10:2255-2270.
220. FLASHER D, KONOPKA K, CHAMOW SM et al.: Liposome targeting to human immunodeficiency virus Type 1-infected cells via recombinant soluble CD4 and CD4 immunoadhesin (CD4-IgG). Biochim. Biophys. Acta (1994) 1194:185-196.
221. SLEPUSHKIN VA, SALEM II, ANDREEV SM, DAZIN P, DÜZGÜNES N: Targeting of liposomes to HIV-infected cells by peptides derived from the CD4 receptor. Biochem. Biophys. Res. Commun. (1996) 227:827-833.
222. BLUME G, CEVC G, CROMMELIN MDJA, BAKKER-WOUDENBERG IAJM, KLUFT C, STORM G: Specific targeting with poly(ethylene glycol)-modified liposomes: Coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim. Biophys. Acta (1993) 1149:180-184.
223. ALLEN TM, BRANDEIS E, HANSEN CB, KAO GY, ZALIPSKY S: A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim. Biophys. Acta (1995) 1237:99-108.
224. GABIZON A, HOROWITZ AT, GOREN D et al.: Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: In vitro studies. Bioconjug. Chem. (1999) 10:289-298.
225. KIRPOTIN D, HONG K, MULLAH N, PAPAHADJOPOULOS D, ZALIPSKY S: Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol). FEBS Lett. (1996) 388:115-118.
226. BOYLE MJ, CONNORS M, FLANIGAN ME et al.: The human HIV/peripheral blood lymphocyte (PBL)-SCID mouse: A modified human PBL-SCID model for the study of HIV pathogenesis and therapy. J. Immunol. (1995) 154:6612-6623.
227. ALDER J, HUI YH, CLEMENT J: Efficacy of AZT therapy in reducing p24 antigen burden in a modified SCID mouse model of HIV infection. Antiviral Res. (1995) 27:85-97.
228. RABIN L, HINCENBERGS M, MORENO MB et al.: Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus Type 1 compounds. Antimicrob. Agents Chemother. (1996) 40:755-762.
229. KANESHIMA H, SHIH CC, NAMIKAWA R et al.: Human immunodeficiency virus infection of human lymph nodes in the SCID-hu mouse. Proc. Natl. Acad. Sci. USA (1991) 88:4523-4527.
230. GIOVANNANGELI C, DIVIACCO S, LABROUSSE V, GRYAZNOV S, CHARNEAU P, HÉLÉNE C: Accessibility of nuclear DNA to triplex-forming oligonucleotides: The integrated HIV-1 provirus as a target. Proc. Natl. Acad. Sci. USA (1997) 94:79-84.
231. PRASEUTH D, GUIEYSSE AL, HÉLÉNE C: Triple helix formation and the antigene strategy for sequence-specific control of gene expression. Biochim. Biophys. Acta (1999) 1489:181-206.
232. BARRE F-X, AIT-SI-ALI S, GIOVANNANGELI C et al.: Unambiguous demonstration of triple-helix directed gene modification. Proc. Natl. Acad. Sci. USA (2000) 97:3084-3088.
233. VASQUEZ KM, NARAYANAN L, GLAZER PM: Specific mutations induced by triplex-forming oligonucleotides in mice. Science (2000) 290:530-533.
234. GIOVANNANGELI C, HÉLÈNE C: Triplex technology take soff. Nat. Biotechnol. (2000) 18:1245-1246.